Market revenue in 2023 | USD 227.2 million |
Market revenue in 2030 | USD 312.5 million |
Growth rate | 4.7% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 62.19% in 2023. Horizon Databook has segmented the Japan pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most advanced countries in this region, and its market is expected to grow rapidly, due to high government spending to curb cancer prevalence. The increase in cancer prevalence can be attributed to rapid growth in the geriatric population. Japan has a median age of 44 years, one of the highest in the world.
In contrast to other Asia Pacific countries, Japan offers country-wide cancer screening programs to combat its growing prevalence. This program offers cancer screening to over 94% of the population. However, stringent policies by regulatory agencies may delay the introduction of newer technologies in the market, which may hamper market growth during the forecast period.
This study, sponsored by the Japanese Heart Foundation and Japan Cardiovascular Research Foundation, along with the Ministry of Education, Culture, Sports, Science & Technology of Japan and Japan Agency for Medical Research & Development, states that as the number of constituent factors of MetS increases, the risk of pancreatic cancer incidence will surge.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan pancreatic cancer diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into Japan pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account